Michael Chorny Laboratory

Led by Michael Chorny, PhD, researchers in the Chorny Laboratory are focused on developing tumor-targeted, nanoparticle-based cancer drugs to treat children with neuroblastoma and other pediatric malignancies. Using ultra small-sized (<100nm) biodegradable particles containing an experimental cancer drug, researchers in the Chorny Laboratory were able to reduce the tumor burden (with no systemic toxicity) in mouse models of neuroblastoma.

Selected Publications

Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Lett. 2015 May 1;360(2):205-12.
Iyer R, Croucher JL, Chorny M, Mangino JL, Alferiev IS, Levy RJ, Kolla V, Brodeur GM.

Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials. 2015 May;51:22-9.
Alferiev IS, Iyer R, Croucher JL, Adamo RF, Zhang K, Mangino JL, Kolla V, Fishbein I, Brodeur GM, Levy RJ, Chorny M.

Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4245-50.
Tengood JE, Alferiev IS, Zhang K, Fishbein I, Levy RJ, Chorny M.